Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bucindolol beta blocker targeted to beta receptors in the heart and vasculature: Subsidiary Intercardia Inc. began a Phase III trial in up to 2,800 patients, wi

Interneuron Pharmaceuticals (IPIC), Lexington, Mass.

Read the full 56 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE